Chardan Capital Markets will host a Leadership Call with HighTide Therapeutics. The call will be moderated by Michael Morabito, PhD, Senior Research Analyst.
May 19, 2020
HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes. HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk fac
May 07, 2020
Approvals Support Clinical Trials in China and Canada for HTD1801 in Primary Sclerosing Cholangitis
November 19, 2019